Dechert LLP‘s Boston-based patent prosecution team is well-known for its capabilities in all patent prosecution matters as well as in portfolio management for its clients. The team’s workload includes advising on IP due diligence and negotiations, and on the sale and acquisition of patent portfolios. The cases are often of considerable value and vary between domestic and international in scope. The life sciences industry is the team’s key focus area and it also has an increasing focus on biologics. The team heads Andrea Reid and Andrew Wilkins are described as being ’very experienced, engaged and responsive lead partners’, with key attorney to note in the team being Chad Davis.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘Very experienced, engaged, and responsive lead partners.'

Key clients

4E Therapeutics
Aer Therapeutics
Agenus
Akamis Bio
Aldeyra Therapeutics
Atlas Ventures
Arcutis
argenx SE
AVEO Oncology / AVEO Pharmaceutical
Bayer Healthcare
Bicycle Therapeutics Limited
Canaan Management
Chiesi Farmaceutici S.p.A.
DiffusionRx
Forbion Capital Partners
Homology Medicines
Ikena Oncology
Ipsen Biosciences
Karuna Therapeutics
Kymera Therapeutics
Longwood Fund
Merck KGaA
Nimbus Therapeutics
Novo Holdings
Ocuphire Pharma
Parthenon Therapeutics
PIC Therapeutics
Rectify Pharmaceuticals
ROME Therapeutics
Solu Therapeutics
SRS Aquiom
Third Harmonic
Vertex Pharmaceuticals

Work highlights

Handled the patent strategy work on behalf of Nimbus Therapeutics’ highly selective, allosteric TYK2 inhibitor portfolio to address multiple immune-mediated diseases, which was acquired by Takeda in December 2022 for $6bn.
Advised Chiesi Farmaceutici S.p.A. on IP analysis in its $1.48bn all-cash transaction to acquire Amryt Pharma Plc.
Handled the patent strategy and IP diligence on behalf of argenx SE on its transcontinental share offering raising $1.1bn in new funds.